AgeneBio Company Profile, Contacts & Intelligence

AgeneBio Overview

AgeneBio, Inc., is an emerging pharmaceutical company dedicated to developing innovative therapeutics that prevent neurodegeneration and preserve and restore cognitive function for unserved patients battling amnestic mild cognitive impairment (aMCI), the symptomatic pre-dementia stage of Alzheimer’s disease, and other neurological and psychiatric diseases. AgeneBio’s novel pipeline of therapies is based on decades of research at Johns Hopkins University and leading research centers worldwide showing that overactivity in the hippocampus contributes to cognitive impairment and drives neurodegeneration if not controlled. This overactivity is a characteristic feature of aMCI. If approved, AgeneBio’s Phase 3-ready lead candidate, AGB101, will be the first and only therapeutic targeting hippocampal overactivity and potentially the first therapeutic to slow progression to, and delay the onset of, Alzheimer’s dementia. AgeneBio also has a novel GABA-A alpha5 small molecule program in late discovery stage with therapeutic potential for a spectrum of untreated conditions including aMCI, autism and schizophrenia. Learn more at www.agenebio.com and follow us on Twitter @AgeneBio.

Headquarters

Baltimore, Md, United States

Website

agenebio.com

Industry

Pharmaceutical Manufacturing

NAICS

Pharmaceutical and Medicine Manufacturing, Medicinal and Botanical Manufacturing

Phone Number

Available in AeroLeads

Company Email

Available in AeroLeads

AgeneBio Contact Intelligence

See which contact channels and departments are represented in the visible AeroLeads data.

AgeneBio People & Org Chart Preview

Sample people records show job titles and whether email or phone data is available without exposing raw contact details.

AgeneBio Workforce Composition

Seniority breakdown across 3 visible profiles.

Compare Similar Companies to AgeneBio

Explore companies in related markets and compare their industry and employee estimates.